

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
06275/004001SERIAL NO.
~~08/265,237~~ 08/736267INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Kjell G.E. Bäckström et al.FILING DATE
June 23, 1994GROUP
~~4806~~ 1813 1817

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BP	AA	5	4	1	9	3	1	5	05/30/95	Rubsamen	128	200.14	—
BP	AB	5	3	5	4	5	6	2	10/11/94	Platz et al.	424	489	—
BP	AC	5	2	0	2	1	2	9	04/13/93	Samejima et al.	424	489	—
BP	AD	5	1	7	9	0	7	9	01/12/93	Hansen et al.	514	4	—
BP	AE	4	9	0	0	7	3	0	02/13/90	Miyauchi	514	12	—
BP	AF	4	7	8	8	2	2	1	11/29/88	Kagatani et al.	514	12	—
BP	AG	4	6	9	0	9	5	2	09/01/87	Kagatani et al.	514	11	—
BP	AH	4	6	1	3	5	0	0	09/23/86	Suzuki et al.	424	85.4	—

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BP	AI	0 360 340	03/28/90	Europe	—	—		✓
	AJ							
	AK							
	AL							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

BP	AM	Olanoff et al., "Method to Enhance Intranasal Peptide Delivery," in "Controlled-Release Technology
		Pharmaceutical Applications," Lee et al., American Chemical Society, 301-309, 1987.
	AN	
	AO	
	AP	

EXAMINER

Benet Prockel, Ph.D.

DATE CONSIDERED

4/10/96

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.